Genotropin
Payments companies reported to CMS as associated with Genotropin. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Genotropin, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Genotropin
These are the largest totals companies reported as associated with Genotropin. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Aristides Maniatis | Centennial, CO | Pediatric Endocrinology | $30,934.44 |
| Bradley Miller | Minneapolis, MN | Pediatric Endocrinology | $20,046.18 |
| Lawrence Silverman | Morristown, NJ | Pediatric Endocrinology | $14,117.27 |
| Carlos Leyva | San Juan, PR | Pediatric Endocrinology | $11,370.30 |
| Marina Ruiz-Montilla | Santurce, PR | Pediatric Endocrinology | $9,070.49 |
| Joel Steelman | Fort Worth, TX | Pediatric Endocrinology | $4,274.36 |
| Mitchell Geffner | Los Angeles, CA | Pediatric Endocrinology | $4,162.00 |
| Lisa Richards | Toledo, OH | Pediatrics (Nurse Practitioner) | $2,706.23 |
| Deanna Aftab Guy | Brentwood, TN | Pediatric Endocrinology | $2,549.75 |
| Eric Gyuricsko | Norfolk, VA | Pediatric Endocrinology | $2,197.57 |
Prescribed Genotropin?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.